PHARMA ONLINE WHITE PAPERS

Katie-Anderson-Chief-Editor

INDUSTRY NEWS

  • Høeg In, Pazdur Out At The FDA

    What an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.

  • 9 Drugs Granted Fast Track By FDA's Voucher Program

    With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.

  • Leaders In The Excipient Market: Region And Type

    Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.

  • Pfizer Strengthens Obesity Foothold With Metsera Acquisition

    After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.

  • FDA Cracks Down On GLP-1 Imports

    GLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.

PHARMACEUTICAL ONLINE CONTENT COLLECTIONS

MilliporeSigma Pharm Online Ebook

 

Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.

More Content Collections

SUPPLIER NEWS

  • Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics
    12/18/2025

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.

  • Driving Pharma 4.0: Flexible & Sustainable Facilities At PHARMAP 2026
    12/18/2025

    The shift towards Pharma 4.0 is revolutionising pharmaceutical manufacturing, introducing highly advanced, digitally interconnected and automated production plants that simplify processes and transform the industry. The future of pharmaceutical facilities is going to be the central theme of discussions at PHARMAP 2026 in Amsterdam on 20-21 April.

  • CDMO Halo Pharma Adds New Gerteis Roller Compactor
    12/18/2025

    Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products.

  • Groninger Apprentices Mark Career Milestones
    12/17/2025

    groninger USA proudly announces the graduation of apprentices Connor Benito and Logan Busteed, who today receive their Associate Degrees in Mechatronics Engineering Technology from Central Piedmont Community College. Both young professionals joined groninger’s highly regarded apprenticeship path and now mark a milestone in their technical careers.

  • CDMO Incog Biopharma Announces $200 Million Manufacturing Expansion In Indiana
    12/17/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment will significantly increase the company’s injectable drug product manufacturing capacity.